Anzeige
Mehr »
Dienstag, 17.02.2026 - Börsentäglich über 12.000 News
Bio-Milliardenmarkt: Steht Organto vor der Neubewertung?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
93 Leser
Artikel bewerten:
(0)

Big Bold Health Launches Large-Scale Randomized Clinical Trial Evaluating Himalayan Tartary Buckwheat Sprout Powder

?Study of 850 participants believed to be the largest randomized, placebo-controlled trial ever conducted on a single food ingredient, brain health, and immunity.

BAINBRIDGE ISLAND, WA / ACCESS Newswire / February 17, 2026 / Big Bold Health today announced the launch of an ongoing randomized, placebo-controlled clinical trial evaluating Himalayan Tartary Buckwheat (HTB) Sprout Powder, a whole-food ingredient rich in naturally occurring plant polyphenols. The study, which has now completed enrollment of 850 participants, is believed to be the largest randomized placebo-controlled trial ever conducted on a single food ingredient focused on brain health and immune function.

This IRB-approved study is designed to evaluate the effects of HTB Sprout Powder using objective clinical measurements under controlled conditions. While outcomes are not yet known, the scale and rigor of the trial reflect growing scientific interest in applying modern clinical research methods to whole foods and dietary interventions.

"This study represents an important evolution in how we evaluate nutrition," said Jeffrey Bland, PhD, Founder and President of Big Bold Health. "For many years, nutrition science has focused on isolated nutrients rather than whole foods. By conducting a large randomized clinical trial on a single food, we hope to contribute to a deeper understanding of how complex plant systems interact with human biology. The goal is to advance the science itself, independent of any predetermined outcome."

Lead on the trial from Big Bold Health is Austin Perlmutter, MD, Chief Science Officer. According to Dr. Perlmutter, the study reflects a broader effort to bring greater scientific clarity to food-based interventions. "Eating certain foods has been convincingly linked to better health, including improved brain function, immune function, and metabolic function," said Dr. Perlmutter. "Our aim is to explore the 'how' with the largest study ever done of its kind. We're studying a uniquely nutrient rich food-sprouted Himalayan Tartary Buckwheat-with a rigorous and transparent process, allowing the data to guide future understanding of how food can promote health. Completing enrollment is an important milestone, and we look forward to sharing results once the study is complete."

Himalayan Tartary Buckwheat is an ancient crop traditionally consumed in parts of Asia and more recently reintroduced to U.S. agriculture through regenerative farming initiatives. Big Bold Health has supported research efforts around the crop as part of its broader mission to explore the intersection of nutrition, immunity, human longevity, and ecological health.

Results from the study will be analyzed following completion of the intervention period and are expected to contribute to the growing body of research examining the role of whole foods in human health.

About Big Bold Health

Big Bold Health is on a mission to establish global awareness of longevity through immune health. From revitalizing lost superfoods to crafting high-quality omega-3 products, Big Bold Health draws from the best immunity interventions nature can offer. With an unparalleled dedication to science, sustainability, and quality, Big Bold Health supports enduring wellness for people, plants, and planet. For more information, visit?https://bigboldhealth.com.

Media Contact

Trish Eury
Senior Director of Communications
trisheury@bigboldhealth.com

SOURCE: Big Bold Health



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/big-bold-healthr-launches-large-scale-randomized-clinical-trial-evalua-1137688

© 2026 ACCESS Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.